

Robert P Frantz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9157924/publications.pdf>

Version: 2024-02-01

158
papers

12,522
citations

38660

50
h-index

25716

108
g-index

160
all docs

160
docs citations

160
times ranked

10287
citing authors

#	ARTICLE	IF	CITATIONS
1	Definitions and Diagnosis of Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D42-D50.	1.2	1,467
2	Predicting Survival in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2010, 122, 164-172.	1.6	1,353
3	Risk stratification and medical therapy of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801889.	3.1	614
4	The REVEAL Registry Risk Score Calculator in Patients Newly Diagnosed With Pulmonary Arterial Hypertension. <i>Chest</i> , 2012, 141, 354-362.	0.4	448
5	Predicting Survival in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2019, 156, 323-337.	0.4	408
6	Outcome Prediction by Quantitative Right Ventricular Function Assessment in 575 Subjects Evaluated for Pulmonary Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 711-721.	1.3	349
7	Effects of the oral endothelin-receptorantagonist bosentan on echocardiographicand doppler measures in patients with pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1380-1386.	1.2	334
8	Portopulmonary hypertension: Results from a 10-year screening algorithm. <i>Hepatology</i> , 2006, 44, 1502-1510.	3.6	322
9	Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C) Tj ETQq1 1 0784314.pdf / Over	0.4	298
10	Right Ventricular Strain for Prediction of Survival in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2011, 139, 1299-1309.	0.4	298
11	Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. <i>Hepatology</i> , 1999, 30, 641-648.	3.6	271
12	Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73). <i>BMJ, The</i> , 2016, 353, i1246.	3.0	266
13	Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction. <i>Circulation</i> , 2018, 137, 1796-1810.	1.6	223
14	Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure. <i>Circulation</i> , 2009, 120, 2170-2176.	1.6	213
15	World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 913-933.	0.3	210
16	Readmissions After Implantation of Axial Flow Left Ventricular Assist Device. <i>Journal of the American College of Cardiology</i> , 2013, 61, 153-163.	1.2	209
17	Accuracy of Doppler Echocardiography in the Assessment of Pulmonary Hypertension in Liver Transplant Candidates. <i>Liver Transplantation</i> , 2000, 6, 453-458.	1.3	176
18	Changes in Renal Function After Implantation of Continuous-Flow Left Ventricular Assist Devices. <i>Journal of the American College of Cardiology</i> , 2012, 59, 26-36.	1.2	167

#	ARTICLE	IF	CITATIONS
19	Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation. <i>Circulation</i> , 2007, 116, 2726-2733.	1.6	162
20	Endothelial Progenitor Cells Are Decreased in Blood of Cardiac Allograft Patients With Vasculopathy and Endothelial Cells of Noncardiac Origin Are Enriched in Transplant Atherosclerosis. <i>Circulation</i> , 2003, 108, 143-149.	1.6	142
21	Acute Cellular Rejection and the Subsequent Development of Allograft Vasculopathy After Cardiac Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 320-327.	0.3	141
22	Role of Serial Quantitative Assessment of Right Ventricular Function by Strain in Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2013, 111, 143-148.	0.7	137
23	Integration of Clinical and Hemodynamic Parameters in the Prediction of Long-term Survival in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2011, 139, 1285-1293.	0.4	124
24	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 227-238.	5.2	122
25	Combined Heart and Liver Transplantation: A Single-Center Experience. <i>Transplantation</i> , 2009, 88, 219-225.	0.5	118
26	Autologous Stem Cell Transplant after Heart Transplant for Light Chain (AL) Amyloid Cardiomyopathy. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 823-829.	0.3	117
27	PVDOMICS. <i>Circulation Research</i> , 2017, 121, 1136-1139.	2.0	113
28	Immediate and Long-term Hemodynamic and Clinical Effects of Sildenafil in Patients With Pulmonary Arterial Hypertension Receiving Vasodilator Therapy. <i>Mayo Clinic Proceedings</i> , 2003, 78, 1207-1213.	1.4	109
29	Echocardiographic Variables After Left Ventricular Assist Device Implantation Associated With Adverse Outcome. <i>Circulation: Cardiovascular Imaging</i> , 2011, 4, 648-661.	1.3	106
30	Impaired Left Ventricular Mechanics in Pulmonary Arterial Hypertension. <i>Circulation: Heart Failure</i> , 2013, 6, 748-755.	1.6	106
31	Sirolimus as Primary Immunosuppression Attenuates Allograft Vasculopathy With Improved Late Survival and Decreased Cardiac Events After Cardiac Transplantation. <i>Circulation</i> , 2012, 125, 708-720.	1.6	105
32	Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1366-1375.	0.3	103
33	Sirolimus in Cardiac Transplantation: Use as a Primary Immunosuppressant in Calcineurin Inhibitor-induced Nephrotoxicity. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 2129-2136.	0.3	90
34	Pericardial Effusions in Pulmonary Arterial Hypertension. <i>Chest</i> , 2013, 144, 1530-1538.	0.4	81
35	Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients. <i>Journal of the American College of Cardiology</i> , 2018, 71, 636-650.	1.2	81
36	Relation of Tissue Displacement and Strain to Invasively Determined Right Ventricular Stroke Volume. <i>American Journal of Cardiology</i> , 2005, 96, 1173-1178.	0.7	79

#	ARTICLE	IF	CITATIONS
37	Reference Values for Right Ventricular Strain in Patients without Cardiopulmonary Disease: A Prospective Evaluation and Meta-Analysis. <i>Echocardiography</i> , 2015, 32, 787-796.	0.3	79
38	Replacement of Calcineurin-Inhibitors With Sirolimus as Primary Immunosuppression in Stable Cardiac Transplant Recipients. <i>Transplantation</i> , 2007, 84, 467-474.	0.5	73
39	Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1472-1487.	2.5	68
40	Causes of Breathing Inefficiency During Exercise in Heart Failure. <i>Journal of Cardiac Failure</i> , 2010, 16, 835-842.	0.7	65
41	Donor-Specific Antibodies to Class II Antigens Are Associated With Accelerated Cardiac Allograft Vasculopathy. <i>Transplantation</i> , 2013, 95, 389-396.	0.5	65
42	Symptom burden, quality of life, and attitudes toward palliative care in patients with pulmonary arterial hypertension: Results from a cross-sectional patient survey. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 1102-1108.	0.3	64
43	Myocardial Contractile Reserve by Dobutamine Stress Echocardiography Predicts Improvement in Ejection Fraction With β -Blockade in Patients With Heart Failure. <i>Circulation</i> , 2003, 108, 2336-2341.	1.6	63
44	Clinical predictors of exercise capacity 1 year after cardiac transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2003, 22, 16-27.	0.3	62
45	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI Cardiovascular Medical Research and Education Fund Workshop Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1661-1670.	2.5	59
46	Increase in Total Plasma Homocysteine Concentration After Cardiac Transplantation. <i>Mayo Clinic Proceedings</i> , 1995, 70, 125-131.	1.4	58
47	Usefulness of the Six-Minute Walk Test After Continuous Axial Flow Left Ventricular Device Implantation to Predict Survival. <i>American Journal of Cardiology</i> , 2012, 110, 1322-1328.	0.7	56
48	Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. <i>World Journal of Transplantation</i> , 2016, 6, 380.	0.6	56
49	Systemic Inflammation and Metabolic Syndrome in Cardiac Allograft Vasculopathy. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 826-833.	0.3	55
50	Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. <i>American Heart Journal</i> , 2005, 149, 541-547.	1.2	54
51	Combined Heart and Kidney Transplantation Provides an Excellent Survival and Decreases Risk of Cardiac Cellular Rejection and Coronary Allograft Vasculopathy. <i>Transplantation Proceedings</i> , 2011, 43, 1871-1876.	0.3	52
52	Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry. <i>Journal of the American Heart Association</i> , 2022, 11, e024969.	1.6	50
53	Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System. <i>Chest</i> , 2016, 150, 27-34.	0.4	48
54	Effects of acute changes in pulmonary wedge pressure on periodic breathing at rest in heart failure patients. <i>American Heart Journal</i> , 2007, 153, 104.e1-104.e7.	1.2	47

#	ARTICLE	IF	CITATIONS
55	Sirolimus As Primary Immunosuppressant Reduces Left Ventricular Mass and Improves Diastolic Function of the Cardiac Allograft. <i>Transplantation</i> , 2008, 86, 1395-1400.	0.5	45
56	Survival in pulmonary arterial hypertension patients awaiting lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 1179-1186.	0.3	42
57	Physician Attitudes toward Palliative Care for Patients with Pulmonary Arterial Hypertension: Results of a Cross-sectional Survey. <i>Pulmonary Circulation</i> , 2014, 4, 504-510.	0.8	42
58	Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire. <i>Chest</i> , 2018, 154, 848-861.	0.4	41
59	Right Ventricular Pressure Waveform and Wave Reflection Analysis in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2007, 132, 37-43.	0.4	40
60	Unraveling the RV Ejection Doppler Envelope. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 1268-1277.	2.3	40
61	Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2018, 154, 126-135.	0.4	40
62	Partial Normalization of the Heart Rate Response to Exercise After Cardiac Transplantation: Frequency and Relationship to Exercise Capacity. <i>Mayo Clinic Proceedings</i> , 2002, 77, 1295-1300.	1.4	38
63	The usefulness of submaximal exercise gas exchange to define pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 1133-1142.	0.3	38
64	The Effects of Nesiritide on Renal Function and Diuretic Responsiveness in Acutely Decompensated Heart Failure Patients With Renal Dysfunction. <i>Journal of Cardiac Failure</i> , 2008, 14, 267-275.	0.7	37
65	Continuous Hemodynamic Monitoring in Patients With Pulmonary Arterial Hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 780-788.	0.3	36
66	Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1301-1326.	0.3	36
67	Combined Heart and Liver Transplant Attenuates Cardiac Allograft Vasculopathy Compared with Isolated Heart Transplantation. <i>Transplantation</i> , 2013, 95, 859-865.	0.5	35
68	Imatinib in Pulmonary Arterial Hypertension: Kit Inhibition. <i>Pulmonary Circulation</i> , 2014, 4, 452-455.	0.8	35
69	Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study. <i>Chest</i> , 2015, 147, 484-494.	0.4	35
70	Influence of sildenafil on lung diffusion during exposure to acute hypoxia at rest and during exercise in healthy humans. <i>European Journal of Applied Physiology</i> , 2008, 103, 421-430.	1.2	34
71	Cardiac Allograft Remodeling After Heart Transplantation Is Associated with Increased Graft Vasculopathy and Mortality. <i>American Journal of Transplantation</i> , 2009, 9, 132-139.	2.6	34
72	The prognostic significance of tricuspid valve regurgitation in pulmonary arterial hypertension. <i>Clinical Respiratory Journal</i> , 2018, 12, 1572-1580.	0.6	34

#	ARTICLE	IF	CITATIONS
73	Impact of Right Ventricular Dysfunction on Short-term and Long-term Mortality in Sepsis. <i>Chest</i> , 2021, 159, 2254-2263.	0.4	33
74	Pulmonary Hypertension in Hereditary Hemorrhagic Telangiectasia. <i>Chest</i> , 2016, 149, 362-371.	0.4	31
75	Repeat length polymorphism of the serotonin transporter gene influences pulmonary artery pressure in heart failure. <i>American Heart Journal</i> , 2007, 153, 426-432.	1.2	30
76	Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Initial Single-Center Experience. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2019, 3, 311-318.	1.2	29
77	Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 696-705.	0.3	28
78	Right ventricular function with hypoxic exercise: effects of sildenafil. <i>European Journal of Applied Physiology</i> , 2007, 102, 87-95.	1.2	27
79	Comprehensive Diagnostic Evaluation of Cardiovascular Physiology in Patients With Pulmonary Vascular Disease. <i>Circulation: Heart Failure</i> , 2020, 13, e006363.	1.6	27
80	Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 751-760.	2.5	27
81	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. <i>Chest</i> , 2020, 157, 955-965.	0.4	26
82	United States Pulmonary Hypertension Scientific Registry. <i>Chest</i> , 2021, 159, 311-327.	0.4	25
83	EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. <i>European Respiratory Journal</i> , 2021, 57, 2000414.	3.1	24
84	Usefulness of High-Density Lipoprotein Cholesterol to Predict Survival in Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2016, 118, 292-297.	0.7	22
85	Heart transplantation for radiation-associated end-stage heart failure. <i>Transplant International</i> , 2000, 13, 162-165.	0.8	21
86	B-Type Natriuretic Peptide Levels and Continuous-Flow Left Ventricular Assist Devices. <i>ASAIO Journal</i> , 2010, 56, 527-531.	0.9	21
87	Diastolic Pulmonary Gradient as a Predictor of Right Ventricular Failure After Left Ventricular Assist Device Implantation. <i>Journal of the American Heart Association</i> , 2019, 8, e012073.	1.6	21
88	Submaximal Exercise Pulmonary Gas Exchange in Left Heart Disease Patients With Different Forms of Pulmonary Hypertension. <i>Journal of Cardiac Failure</i> , 2015, 21, 647-655.	0.7	20
89	Outcomes After Noncardiac Surgery for Patients with Pulmonary Hypertension: A Historical Cohort Study. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2020, 34, 1506-1513.	0.6	20
90	Inpatient Palliative Care Use in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2020, 158, 2568-2578.	0.4	20

#	ARTICLE	IF	CITATIONS
91	The effects of sildenafil and acetazolamide on breathing efficiency and ventilatory control during hypoxic exercise. <i>European Journal of Applied Physiology</i> , 2009, 106, 509-515.	1.2	19
92	Predictors and Clinical Outcomes of Vasoplegia in Patients Bridged to Heart Transplantation With Continuous-Flow Left Ventricular Assist Devices. <i>Journal of the American Heart Association</i> , 2019, 8, e013108.	1.6	19
93	Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 948-955.	0.3	18
94	Obesity in Pulmonary Arterial Hypertension. The Pulmonary Hypertension Association Registry. <i>Annals of the American Thoracic Society</i> , 2021, 18, 229-237.	1.5	18
95	Heart-After-Liver Transplantation Attenuates Rejection of Cardiac Allografts in Sensitized Patients. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1331-1340.	1.2	18
96	Recipient Selection and Management Before Cardiac Transplantation. <i>American Journal of the Medical Sciences</i> , 1997, 314, 139-152.	0.4	18
97	Baseline and Serial Neurohormones in Patients With Congestive Heart Failure Treated With and Without Bucindolol: Results of the Neurohumoral Substudy of the Beta-Blocker Evaluation of Survival Study (BEST). <i>Journal of Cardiac Failure</i> , 2007, 13, 437-444.	0.7	17
98	Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 811-816.	0.3	17
99	A Pulmonary Hypertension Gas Exchange Severity (PH-GXS) Score to Assist With the Assessment and Monitoring of Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2012, 109, 1066-1072.	0.7	17
100	TPMT genetic variants are associated with increased rejection with azathioprine use in heart transplantation. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 658-665.	0.7	17
101	Novel Left Heart Catheterization Ramp Protocol to Guide Hemodynamic Optimization in Patients Supported With Left Ventricular Assist Device Therapy. <i>Journal of the American Heart Association</i> , 2019, 8, e010232.	1.6	17
102	Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry. <i>Pulmonary Circulation</i> , 2021, 11, 1-10.	0.8	17
103	Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 35-46.	5.2	17
104	ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 1135-1194.	0.3	17
105	Lipoprotein-Associated Phospholipase A2 Predicts Progression of Cardiac Allograft Vasculopathy and Increased Risk of Cardiovascular Events in Heart Transplant Patients. <i>Transplantation</i> , 2008, 85, 963-968.	0.5	16
106	Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation Procedure. <i>Chest</i> , 2017, 152, 1128-1134.	0.4	16
107	Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type 5 inhibitors. <i>Pulmonary Circulation</i> , 2020, 10, 1-11.	0.8	15
108	Development of prognostic tools in pulmonary arterial hypertension: Lessons from modern day registries. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1049-1060.	1.8	14

#	ARTICLE	IF	CITATIONS
109	A Multicenter, Retrospective Study of Patients with Pulmonary Arterial Hypertension Transitioned from Parenteral Prostacyclin Therapy to Inhaled Iloprost. <i>Pulmonary Circulation</i> , 2013, 3, 381-388.	0.8	14
110	Conversion From Sildenafil to Tadalafil. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 550-557.	1.0	14
111	Treadmill testing improves survival prediction models in pulmonary arterial hypertension. <i>American Heart Journal</i> , 2011, 162, 1011-1017.	1.2	13
112	Cardiac allograft hypertrophy is associated with impaired exercise tolerance after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 1153-1160.	0.3	12
113	Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class <scp>IV</scp> Chronic Thromboembolic Pulmonary Hypertension. <i>Pharmacotherapy</i> , 2017, 37, e76-e81.	1.2	12
114	Long-term results of the DelIVery for Pulmonary Arterial Hypertension trial. <i>Pulmonary Circulation</i> , 2019, 9, 204589401987861.	0.8	12
115	Prediction of Health-related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 761-764.	2.5	12
116	The Pharmacokinetics of Racemic Verapamil in Patients with Impaired Renal Function. <i>Journal of Clinical Pharmacology</i> , 1991, 31, 45-53.	1.0	11
117	Techniques of Immunosuppression After Cardiac Transplantation. <i>Mayo Clinic Proceedings</i> , 1992, 67, 586-595.	1.4	11
118	A Possible Role for Systemic Hypoxia in the Reactive Component of Pulmonary Hypertension in Heart Failure. <i>Journal of Cardiac Failure</i> , 2013, 19, 50-59.	0.7	11
119	Hemodynamic Ranges During Daily Activities and Exercise Testing in Patients With Pulmonary Arterial Hypertension. <i>Journal of Cardiac Failure</i> , 2014, 20, 485-491.	0.7	11
120	Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1372-1380.	0.3	11
121	Thrombocytopenia independently predicts death in idiopathic PAH. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2019, 48, 34-38.	0.8	11
122	EFFECTS OF PENTOXIFYLLINE ON RENAL FUNCTION AND BLOOD PRESSURE IN CARDIAC TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1997, 63, 1607-1610.	0.5	11
123	Early Trends in N-Terminal Pro-Brain Natriuretic Peptide Values After Left Ventricular Assist Device Implantation for Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2014, 114, 1257-1263.	0.7	10
124	Dramatic and sustained responsiveness of pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension to vasodilator therapy. <i>Respiratory Medicine Case Reports</i> , 2015, 14, 13-15.	0.2	10
125	Early Gains in Renal Function Following Implantation of HeartMate II Left Ventricular Assist Devices May Not Persist to One Year. <i>ASAIO Journal</i> , 2017, 63, 401-407.	0.9	10
126	Whither Anticoagulation in Pulmonary Arterial Hypertension?. <i>Circulation</i> , 2015, 132, 2360-2362.	1.6	8

#	ARTICLE	IF	CITATIONS
127	Hemodynamic monitoring in pulmonary arterial hypertension. <i>Expert Review of Respiratory Medicine</i> , 2011, 5, 173-178.	1.0	7
128	Features of Cardiac Allograft Coronary Endothelial Dysfunction. <i>American Journal of Cardiology</i> , 2009, 103, 1154-1158.	0.7	6
129	Pulmonary arterial hypertension or left heart disease with pulmonary hypertension? Toward noninvasive clarity, but time for a new paradigm. <i>European Respiratory Journal</i> , 2015, 46, 299-302.	3.1	6
130	Integrated Use of Perfusion SPECT/CTA Fusion Imaging and Pulmonary Balloon Angioplasty for Chronic Pulmonary Thromboembolism. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 532-534.	1.1	6
131	Early intervention: should we conduct therapeutic trials for mild pulmonary hypertension before onset of symptoms?. <i>Pulmonary Circulation</i> , 2019, 9, 204589401984561.	0.8	6
132	Comprehensive echocardiographic evaluation of the right heart in patients with pulmonary vascular diseases: the PVDOMICS experience. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 958-969.	0.5	6
133	REPLACE and the role of riociguat in pulmonary arterial hypertension therapy. <i>Lancet Respiratory Medicine</i> , 2021, 9, 546-547.	5.2	6
134	Topic-Based, Recent Literature Review on Pulmonary Hypertension. <i>Mayo Clinic Proceedings</i> , 2021, 96, 3109-3121.	1.4	6
135	Transcatheter Nonductal Reverse Potts Shunt Creation in Pulmonary Arterial Hypertension. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011315.	1.4	6
136	Characterization of Prostacyclin-associated Leg Pain in Patients with Pulmonary Arterial Hypertension. <i>Annals of the American Thoracic Society</i> , 2017, 14, 206-212.	1.5	6
137	Beta blockade in patients with congestive heart failure. <i>Postgraduate Medicine</i> , 2000, 108, 103-118.	0.9	5
138	Pulmonary Arterial Hypertension Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting. <i>Pulmonary Circulation</i> , 2020, 10, 1-9.	0.8	5
139	Resolution of severe pulmonary arterial hypertension complicating adult-onset Still's disease. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1140-1144.	0.3	4
140	The Usefulness of Submaximal Exercise Gas Exchange in Pulmonary Arterial Hypertension: A Case Series. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2010, 4, 117954842020100.	0.5	3
141	COUNTERPOINT: Should the New Definition of PH Be the Clinical Practice Standard? No. <i>Chest</i> , 2020, 157, 766-768.	0.4	3
142	The usefulness of submaximal exercise gas exchange in pulmonary arterial hypertension: a case series. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2010, 4, 35-40.	0.5	3
143	Response to Letter Regarding Article, "Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure: Analysis From the Sudden Cardiac Death in Heart Failure Trial". <i>Circulation</i> , 2010, 122, .	1.6	1
144	Donor Pre-Treatment With Dopamine. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1778-1779.	1.2	1

#	ARTICLE	IF	CITATIONS
145	Diagnostic Dilemmas in Pulmonary Hypertension. Heart Failure Clinics, 2012, 8, 331-352.	1.0	1
146	Ambulatory Hemodynamic Monitoring in Pulmonary Arterial Hypertension. Advances in Pulmonary Hypertension, 2008, 7, 405-410.	0.1	1
147	Pulmonary Hypertension in Chronic Heart and Lung Disease. Respiratory Medicine, 2015, , 93-113.	0.1	1
148	Next-generation sequencing identifies a cryptic <i>BMPR2</i> mutation in hereditary pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-4.	0.8	1
149	Recipient Selection and Management Before Cardiac Transplantation. American Journal of the Medical Sciences, 1997, 314, 139-152.	0.4	0
150	Bosentan for pulmonary hypertension and other pulmonary diseases: emerging evidence. Future Cardiology, 2008, 4, 459-468.	0.5	0
151	Response. Chest, 2018, 154, 1262-1264.	0.4	0
152	Rebuttal From Dr Frantz. Chest, 2020, 157, 768-769.	0.4	0
153	Cardiac and Lung Transplantation and the Right Heart. , 2021, , 317-329.		0
154	The effects of sildenafil and acetazolamide on breathing efficiency during hypoxic exercise. FASEB Journal, 2008, 22, 1173.13.	0.2	0
155	Cardiac and Lung Transplantation. , 2014, , 291-303.		0
156	PH Grand Rounds: Puzzling Etiology of Pulmonary Hypertension Resolved. Advances in Pulmonary Hypertension, 2014, 13, 65-67.	0.1	0
157	The Future of Pulmonary Hypertension. , 2016, , 359-367.		0
158	Positioning Newer Agents: Riociguat, Selexipag, and Oral Treprostinil in the Current Landscape. Advances in Pulmonary Hypertension, 2017, 15, 193-197.	0.1	0